Rohto Pharmaceutical Co (4527) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4527 Analyst Ratings

Moderate Buy

1 Buy

1 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Rohto

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4527 Stock 12 Month Forecast

Average Price Target

¥2,790.00

▲(8.98% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Rohto Pharmaceutical Co in the last 3 months. The average price target is ¥2,790.00 with a high forecast of ¥2,980.00 and a low forecast of ¥2,600.00. The average price target represents a 8.98% change from the last price of ¥2,560.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2002":"¥2,002","3325":"¥3,325","2332.75":"¥2,332.8","2663.5":"¥2,663.5","2994.25":"¥2,994.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2980,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.98K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2790,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.79K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥2.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2002,2332.75,2663.5,2994.25,3325],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2481.5,2519.846153846154,2558.1923076923076,2596.5384615384614,2634.8846153846152,2673.230769230769,2711.576923076923,2749.923076923077,2788.269230769231,2826.6153846153848,2864.9615384615386,2903.3076923076924,2941.653846153846,{"y":2980,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2481.5,2505.230769230769,2528.9615384615386,2552.6923076923076,2576.423076923077,2600.153846153846,2623.8846153846152,2647.6153846153848,2671.346153846154,2695.076923076923,2718.8076923076924,2742.5384615384614,2766.269230769231,{"y":2790,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2481.5,2490.6153846153848,2499.730769230769,2508.846153846154,2517.9615384615386,2527.076923076923,2536.1923076923076,2545.3076923076924,2554.423076923077,2563.5384615384614,2572.653846153846,2581.769230769231,2590.8846153846152,{"y":2600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3310.417,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3324.12,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3273.037,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2859.114,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2134.012,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.013,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2368.357,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2003.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2030.162,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2162.068,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2520.594,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2492,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2481.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥2,980

Average Price Target¥2,790

Lowest Price Target¥2,600

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Hisae Kawamoto

Jefferies

¥2,980

Buy

16.41%

Upside

Upgraded

12/23/25

Rohto Pharmaceutical Co (RPHCF) was upgraded to a Buy Rating at Jefferies

Unknown Analyst

UBS

Not Ranked

UBS

¥2,600

Hold

1.56%

Upside

Initiated

12/12/25

Rohto Pharmaceutical Co (RPHCF) Gets a Hold from UBS

Hiroki Watanabe

Citi

¥2,100→¥2,700

Hold

5.47%

Upside

Reiterated

09/04/25

Rohto Pharmaceutical Co Ltd (4527:JP) PT Raised to JPY2,700 at CitiCiti analyst Hiroki Watanabe raised the price target on Rohto Pharmaceutical Co Ltd (4527:JP) to JPY2,700.00 (from JPY2,100.00) while maintaining a Neutral rating.

Akiko Kuwahara

J.P. Morgan

¥2,700→¥2,900

Buy

13.28%

Upside

Reiterated

08/27/25

J.P. Morgan Remains a Buy on Rohto Pharmaceutical Co (RPHCF)

Wakako Sato

Morgan Stanley

¥3,900→¥3,500

Buy

36.72%

Upside

Reiterated

06/30/25

Morgan Stanley Keeps Their Buy Rating on Rohto Pharmaceutical Co (RPHCF)

Kyoichiro Shigemura

Nomura

¥3,240→¥2,750

Buy

7.42%

Upside

Reiterated

05/29/25

Rohto Pharmaceutical Co (RPHCF) Gets a Buy from Nomura

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

¥3,100→¥2,750

Buy

7.42%

Upside

Reiterated

05/14/25

Target Price Changes; PT lowered to ¥2750

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Hisae Kawamoto

Jefferies

¥2,980

Buy

16.41%

Upside

Upgraded

12/23/25

Rohto Pharmaceutical Co (RPHCF) was upgraded to a Buy Rating at Jefferies

Unknown Analyst

UBS

Not Ranked

UBS

¥2,600

Hold

1.56%

Upside

Initiated

12/12/25

Rohto Pharmaceutical Co (RPHCF) Gets a Hold from UBS

Hiroki Watanabe

Citi

¥2,100→¥2,700

Hold

5.47%

Upside

Reiterated

09/04/25

Akiko Kuwahara

J.P. Morgan

¥2,700→¥2,900

Buy

13.28%

Upside

Reiterated

08/27/25

J.P. Morgan Remains a Buy on Rohto Pharmaceutical Co (RPHCF)

Wakako Sato

Morgan Stanley

¥3,900→¥3,500

Buy

36.72%

Upside

Reiterated

06/30/25

Morgan Stanley Keeps Their Buy Rating on Rohto Pharmaceutical Co (RPHCF)

Kyoichiro Shigemura

Nomura

¥3,240→¥2,750

Buy

7.42%

Upside

Reiterated

05/29/25

Rohto Pharmaceutical Co (RPHCF) Gets a Buy from Nomura

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

¥3,100→¥2,750

Buy

7.42%

Upside

Reiterated

05/14/25

Target Price Changes; PT lowered to ¥2750

Stocks with the Highest Top Analyst Consensus in the Consumer Defensive Sector

xxx

Find stocks in the Consumer Defensive sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rohto Pharmaceutical Co

3 Months

xxx

Success Rate

2/5 ratings generated profit

Average Return

+2.36%

upgraded a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.36% per trade.

1 Year

Akiko KuwaharaJ.P. Morgan

Success Rate

4/8 ratings generated profit

Average Return

-2.43%

reiterated a buy rating 5 months ago

Copying Akiko Kuwahara's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.43% per trade.

2 Years

xxx

Success Rate

4/8 ratings generated profit

Average Return

+0.30%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4527 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4527 has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 4527 average Analyst price target in the past 3 months is 2,790.00.

Each month's total comprises the sum of three months' worth of ratings.

4527 Financial Forecast

4527 Earnings Forecast

Next quarter’s earnings estimate for 4527 is ¥44.11 with a range of ¥39.38 to ¥48.84. The previous quarter’s EPS was ¥26.03. 4527 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.98% of the time in the same period. In the last calendar year 4527 has Performed in-line its overall industry.

4527 Sales Forecast

Next quarter’s sales forecast for 4527 is ¥91.51B with a range of ¥88.80B to ¥96.10B. The previous quarter’s sales results were ¥82.29B. 4527 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 52.41% of the time in the same period. In the last calendar year 4527 has Performed in-line its overall industry.

4527 Stock Forecast FAQ

What is JP:4527’s average 12-month price target, according to analysts?

Based on analyst ratings, Rohto Pharmaceutical Co’s 12-month average price target is 2,790.00.

What is JP:4527’s upside potential, based on the analysts’ average price target?

Rohto Pharmaceutical Co has 8.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Rohto Pharmaceutical Co a Buy, Sell or Hold?

Rohto Pharmaceutical Co has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.

What is Rohto Pharmaceutical Co’s share price target?

The average share price target for Rohto Pharmaceutical Co is 2,790.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥2,980.00 ,and the lowest forecast is ¥2,600.00. The average share price target represents 8.98% Increase from the current price of ¥2,560.

What do analysts say about Rohto Pharmaceutical Co?

Rohto Pharmaceutical Co’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Rohto Pharmaceutical Co?

To buy shares of JP:4527, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Rohto Pharmaceutical Co (4527) Stock Forecast & Price Target

4527 Analyst Ratings

4527 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rohto Pharmaceutical Co

4527 Analyst Recommendation Trends

4527 Financial Forecast

4527 Earnings Forecast

4527 Sales Forecast

4527 Stock Forecast FAQ

Detailed List of Analyst Forecasts